Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets
The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and s...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-10-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1459 |
| _version_ | 1827062780947070976 |
|---|---|
| author | N. A. Totolyan V. M. Alifirova K. Z. Bakhtiyarova A. N. Boyko Ya. V. Vlasov Z. A. Goncharova M. N. Zakharova D. S. Kasatkin S. V. Kotov A. I. Nilov S. A. Sivertseva A. A. Sokolova N. N. Spirin F. A. Khabirov D. Paradnika |
| author_facet | N. A. Totolyan V. M. Alifirova K. Z. Bakhtiyarova A. N. Boyko Ya. V. Vlasov Z. A. Goncharova M. N. Zakharova D. S. Kasatkin S. V. Kotov A. I. Nilov S. A. Sivertseva A. A. Sokolova N. N. Spirin F. A. Khabirov D. Paradnika |
| author_sort | N. A. Totolyan |
| collection | DOAJ |
| description | The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS. |
| first_indexed | 2024-04-10T02:00:51Z |
| format | Article |
| id | doaj.art-5f178b23c350496eb61e04a1caa188bb |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2025-02-18T20:02:18Z |
| publishDate | 2020-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-5f178b23c350496eb61e04a1caa188bb2024-10-17T16:15:27ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422020-10-0112513814510.14412/2074-2711-2020-5-138-1451060Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tabletsN. A. Totolyan0V. M. Alifirova1K. Z. Bakhtiyarova2A. N. Boyko3Ya. V. Vlasov4Z. A. Goncharova5M. N. Zakharova6D. S. Kasatkin7S. V. Kotov8A. I. Nilov9S. A. Sivertseva10A. A. Sokolova11N. N. Spirin12F. A. Khabirov13D. Paradnika14Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaSiberian State Medical University, Ministry of Health of RussiaG.G. Kuvatov Republican Clinical Hospital, Republican Center for Multiple Sclerosis; Bashkir State Medical University, Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Department of Neuroimmunology, Federal Center of Brain and Neurotechnologies, Federal Biomedical Agency of RussiaSamara State Medical University, Ministry of Health of RussiaRostov State Medical University, Ministry of Health of RussiaResearch Center of NeurologyYaroslavl State Medical University, Ministry of Health of RussiaM.F. Vladimirsky Moscow Regional Research Clinical InstituteV.D. Seredavin Samara Regional Clinical HospitalAO «Neftyanik» Primary Healthcare Unit, Tyumen Regional Center for Multiple SclerosisKhanty-Mansi State Medical Academy; District Clinical HospitalYaroslavl State Medical University, Ministry of Health of RussiaKazan State Medical Academy, Branch, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia; Republican Clinical Neurology CenterOOO «Merk»OOO «Merk»The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS.https://nnp.ima-press.net/nnp/article/view/1459highly active multiple sclerosisdisease-modifying drugs for multiple sclerosiscladribine tablets |
| spellingShingle | N. A. Totolyan V. M. Alifirova K. Z. Bakhtiyarova A. N. Boyko Ya. V. Vlasov Z. A. Goncharova M. N. Zakharova D. S. Kasatkin S. V. Kotov A. I. Nilov S. A. Sivertseva A. A. Sokolova N. N. Spirin F. A. Khabirov D. Paradnika Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets Неврология, нейропсихиатрия, психосоматика highly active multiple sclerosis disease-modifying drugs for multiple sclerosis cladribine tablets |
| title | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets |
| title_full | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets |
| title_fullStr | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets |
| title_full_unstemmed | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets |
| title_short | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets |
| title_sort | recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets |
| topic | highly active multiple sclerosis disease-modifying drugs for multiple sclerosis cladribine tablets |
| url | https://nnp.ima-press.net/nnp/article/view/1459 |
| work_keys_str_mv | AT natotolyan recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT vmalifirova recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT kzbakhtiyarova recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT anboyko recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT yavvlasov recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT zagoncharova recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT mnzakharova recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT dskasatkin recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT svkotov recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT ainilov recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT sasivertseva recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT aasokolova recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT nnspirin recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT fakhabirov recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets AT dparadnika recommendationsforswitchingpatientswithhighlyactivemultiplesclerosisfromotherdiseasemodifyingdrugsformultiplesclerosistocladribinetablets |